Search
Iopamidol
go.drugbank.com/drugs/DB08947ApprovedInvestigationalIopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household settingCetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. … [A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.
Clorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitIn September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. … Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction, and its continued use may lead to significant physical dependence.
Eliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigationalThe results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers. … In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs.
Synonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamideLipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedThe average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449]. … It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia.
Products: LONQUEX SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6MG/0.6MLRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [A260192] On the other hand, MuSK activation can trigger the clustering of AChR at the NMJ, guide the innervation of motor neurons toward AChR-dense areas, and anchor acetylcholinesterase.
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663] … [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.
Categories: Drugs for Treatment of TuberculosisSynonyms: (+)-2,2'-(ethylenediimino)di-1-butanol, (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamineVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalEfficacy and safety of vinflunine has not been studied in patients with performance status of 2 or less. … Having an incidence of 429,700 new cases per year worldwide, urothelial carcinoma of the bladder is one of the most common malignancies that mostly affects individuals aged 50–79 years [A32626].
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Chloramphenicol succinate
go.drugbank.com/drugs/DB07565Approved[A204065] Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias. … [L14174] Chloramphenicol succinate was granted FDA approval on 20 February 1959.[L12711]